Crossmark

The Combination of Insulin-Like Growth Factor Receptor 1 (IGF1R) Antibody Cixutumumab and Mitotane as a First-Line Therapy for Patients with Recurrent/Metastatic Adrenocortical Carcinoma: a Multi-institutional NCI-Sponsored Trial

Crossref DOI link: https://doi.org/10.1007/s12672-014-0182-1

Published Online: 2014-05-22

Published Print: 2014-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lerario, Antonio M.

Worden, Francis P.

Ramm, Carole A.

Hasseltine, Elizabeth A.

Stadler, Walter M.

Else, Tobias

Shah, Manisha H.

Agamah, Edem

Rao, Krishna

Hammer, Gary D.
License Information

Text and Data Mining valid from 2014-05-22

Version of Record valid from 2014-05-22
More Information

Article History

Received: 12 February 2014

Accepted: 2 May 2014

First Online: 22 May 2014

Free to read: This content has been made available to all.

Updates are available Erratum dated 2014-09-06

Click to view Erratum: https://doi.org/10.1007/s12672-014-0201-2